Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.43 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]. Market Position - As of August 22, Cofoe Medical's stock closed at 40.71 yuan, down 1.19%, with a rolling price-to-earnings (PE) ratio of 28.19 times, and a total market capitalization of 8.512 billion yuan [1]. - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing Cofoe Medical at the 55th position within the industry [1][3]. Capital Flow - On August 22, the company experienced a net outflow of 21.48 million yuan in principal funds, continuing a trend of outflows over the past five days, totaling 21.12 million yuan [1].

截至2025年一季报，共有5家机构持仓可孚医疗，其中基金5家，合计持股数634.40万股，持股市值2.11 亿元。 可孚医疗科技股份有限公司的主营业务是医疗器械研发、生产、销售和服务。公司的主要产品是血糖系 统、尿酸系统、血压计、血氧仪、红外线体温计、胃幽门螺杆菌快速检测试纸、早孕检测试纸、胎心 仪、听诊器、轮椅、代步车、护理床、移位机、听力计、助听器、助行器、腋下拐、手杖、敷贴/敷料 类、口罩、手套、医用防护服、纱布/绷带类、棉球/棉签/棉片类、消毒产品、口腔护理、呼吸机、制氧 机、氧立得手提便携式制氧器、氧气袋、雾化器、鼻腔护理、理疗仪、按摩器、艾叶及制成品、温灸产 品、拔罐器、刮痧板。公司荣获2023-2024年度中国药品零售市场潜力品牌、湖南省最受残疾人欢迎辅 具品牌、湖南省消费品工业"三品"标杆企业等荣誉，"可孚""Cofoe"及"背背佳"商标入选长沙重点商标保 护名录。 8月20日，可孚医疗今日收盘42.0元，下跌1.50%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到29.08倍，总市值87.82亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.32倍，行业中值 ...

最新一期业绩显示，2025年一季报，公司实现营业收入7.38亿元，同比-8.59%；净利润9142.51万元，同 比-9.68%，销售毛利率52.17%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13可孚医疗26.3525.521.6379.56亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗 17.1715.911.40110.05亿6奥美医疗17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德莱 18.3218.341.5239.49亿9维力医疗18.6219.892.3443.64亿10奥泰生物18.7119.731.5159.67亿11鱼跃医疗 20.1519.762.72356.78亿12三鑫医疗20.8121.623.6549.16亿 来源：金融界 8月11日，可孚医疗今日 ...

8月1日，可孚医疗今日收盘38.39元，上涨4.09%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到26.58倍，创107天以来新低，总市值80.27亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.65倍，行业中值37.22倍，可孚医疗排 名第53位。 股东方面，截至2025年6月20日，可孚医疗股东户数19000户，较上次增加0户，户均持股市值35.28万 元，户均持股数量2.76万股。 可孚医疗科技股份有限公司的主营业务是医疗器械研发、生产、销售和服务。公司的主要产品是血糖系 统、尿酸系统、血压计、血氧仪、红外线体温计、胃幽门螺杆菌快速检测试纸、早孕检测试纸、胎心 仪、听诊器、轮椅、代步车、护理床、移位机、听力计、助听器、助行器、腋下拐、手杖、敷贴/敷料 类、口罩、手套、医用防护服、纱布/绷带类、棉球/棉签/棉片类、消毒产品、口腔护理、呼吸机、制氧 机、氧立得手提便携式制氧器、氧气袋、雾化器、鼻腔护理、理疗仪、按摩器、艾叶及制成品、温灸产 品、拔罐器、刮痧板。公司荣获2023-2024年度中国药品零售市场潜力品牌、湖南省最受残疾人欢迎辅 具品牌、湖南省消费品工业"三品" ...

Core Viewpoint - Cofoe Medical's stock closed at 37.02 yuan, with a rolling PE ratio of 25.63 times, and a total market value of 7.741 billion yuan, indicating a relatively lower valuation compared to the industry average [1][2]. Company Overview - Cofoe Medical specializes in the research, production, sales, and service of medical devices, with a diverse product range including blood glucose systems, blood pressure monitors, and various medical consumables [2]. - The company has received several accolades, including recognition as a potential brand in the Chinese retail pharmaceutical market for 2023-2024 and being listed among the key trademark protection catalog in Changsha [2]. Financial Performance - In the first quarter of 2025, Cofoe Medical reported revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.425 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]. Industry Comparison - The average PE ratio for the medical device industry is 55.46 times, with a median of 37.74 times, positioning Cofoe Medical at the 51st rank within the industry [1][3]. - Cofoe Medical's PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [3].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Cofoe Medical, indicating a decline in revenue and profit in the latest quarterly report [2][3] - As of July 10, Cofoe Medical's stock closed at 34.68 yuan, with a 3.12% increase, and a rolling PE ratio of 24.01, marking a new low in 66 days [1] - The total market capitalization of Cofoe Medical is 7.251 billion yuan, which is significantly lower than the industry average PE ratio of 51.40 and median of 37.27 [1][3] Group 2 - Cofoe Medical specializes in the research, production, sales, and service of medical devices, with a diverse product range including blood glucose systems, blood pressure monitors, and various medical supplies [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.425 million yuan, down 9.68% [2] - The gross profit margin for Cofoe Medical stands at 52.17%, indicating a relatively stable profitability despite the decline in revenue and profit [2]

序号股票简称PE(TTM)PE(静)市净率总市值(元)13可孚医疗22.8922.171.4169.13亿行业平均 49.5647.474.64106.50亿行业中值36.1837.862.4148.50亿1英科医疗9.3810.120.83148.24亿2九安医疗 10.1310.250.80171.03亿3新华医疗14.3913.331.1792.22亿4振德医疗14.5813.740.9352.92亿5康德莱 15.0415.051.2532.41亿6奥美医疗15.0914.791.5554.52亿7山东药玻15.1115.161.74142.94亿8维力医疗 15.9616.591.8736.40亿9九强生物15.9814.861.9679.13亿10奥泰生物16.4017.291.3252.31亿11安杰思 17.4017.602.1051.64亿12三鑫医疗18.4618.473.0442.00亿 6月16日，可孚医疗今日收盘33.06元，下跌1.67%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到22.89倍，总市值69.13亿元。 来源：金融界 可孚医疗科技股份有限公司的主营业 ...

Group 1 - The core business of the company is the research, production, sales, and service of medical devices, with a wide range of products including blood glucose systems, blood pressure monitors, and various medical supplies [2] - As of the first quarter of 2025, the company reported a revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.43 million yuan, down 9.68%, with a gross profit margin of 52.17% [2] - The company has received several honors, including being recognized as a potential brand in the Chinese drug retail market for 2023-2024 and as a leading brand for assistive devices in Hunan Province [2] Group 2 - The company's current price-to-earnings (PE) ratio is 22.92, significantly lower than the industry average of 49.40 and the industry median of 36.13, ranking it 50th in the industry [1][3] - The total market capitalization of the company is 6.921 billion yuan [1] - As of the first quarter of 2025, 17 institutions hold shares in the company, with a total holding of 27.4022 million shares valued at 938 million yuan [1]